NCT06003777View on ClinicalTrials.gov

A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

February 20, 2024

Study Completion Date

February 20, 2024

Conditions
Healthy Participants
Interventions
DRUG

PF-06954522

PF-06954522 will be administered as oral suspensions as escalating single doses to be determined.

DRUG

Placebo

Placebo will be administered as oral suspensions as escalating single doses to be determined.

Trial Locations (1)

06511

Pfizer Clinical Research Unit - New Haven, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06003777 - A Study to Learn How Different Amounts of the Study Medicine Called PF-06954522 Are Tolerated and Act in the Body in Healthy Adults | Biotech Hunter | Biotech Hunter